▎ 摘　　要

NOVELTY - Use of graphene oxide or its regulatory molecules is claimed for use in the preparation of drugs for inhibiting the apoptosis of Ad-MSCs induced by high glucose, preferably the regulatory molecule of graphene oxide is Linc 00324. USE - Graphene oxide or its regulatory molecules for use in the preparation of drugs for inhibiting the apoptosis of Ad-MSCs induced by high glucose, and for promoting diabetic wound repair, preferably the regulatory molecule of graphene oxide is Linc 00324 (all claimed). ADVANTAGE - The graphene oxide or its regulatory molecules found that graphene oxide exerts its function of inhibiting the apoptosis of Ad-MSC by regulating Linc00324 and thus promotes the repair of diabetic wounds, and it is possible to develop in vitro cultured Ad-MSC inhibitors of apoptosis and drugs to promote diabetic wound repair. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) a drug for inhibiting the apoptosis of Ad-MSCs induced by high glucose, which comprises an inhibitor of graphene oxide or its regulatory molecules, preferably, the regulation molecule of graphene oxide is Linc00324, and the Linc 00324 inhibitor includes an agent that inhibits the expression of Linc 00324; (2) a medicine for promoting diabetic wound repair, which comprises graphene oxide or an inhibitor of its regulatory molecules; (3) a pharmaceutical composition for inhibiting the apoptosis of Ad-MSCs induced by high glucose or promoting the repair of diabetic wounds, which comprises graphene oxide, at least one other active pharmaceutical ingredient and/or at least one other non-pharmaceutical active ingredient, inhibitors of graphene oxide regulatory molecules, at least one other pharmaceutical active ingredient and/or at least one other non-pharmaceutical active ingredient, graphene oxide, inhibitor of graphene oxide regulatory molecules, at least one other active pharmaceutical ingredient and/or at least one other non-pharmaceutical active ingredient; (4) a method for inhibiting the apoptosis of Ad-MSCs induced by high glucose in vitro, which comprises applying graphene oxide or an inhibitor of its regulatory molecule; (5) a method for screening drugs that inhibit the apoptosis of Ad-MSCs induced by high glucose, which comprises contacting a system expressing a regulatory molecule of graphene oxide with a candidate compound, and it is determined whether the candidate compound changes the expression of the regulatory molecule of graphene oxide; and (6) a method of screening drugs that promote diabetic wound repair, which comprises contacting a system expressing a regulatory molecule of graphene oxide with a candidate compound.